|
Study of Transfusion-Transmitted Infections Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Study of Transfusion-Transmitted Infections conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Study of Transfusion-Transmitted Infections Clinical research trials and Study of Transfusion-Transmitted Infections health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Study of Transfusion-Transmitted Infections. Study of Transfusion-Transmitted Infections Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Study of Transfusion-Transmitted Infections clinical trial. Test subjects typically receive the most expert healthcare available for their Study of Transfusion-Transmitted Infections condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of Transfusion-Transmitted Infections  Study of Transfusion-Transmitted Infections
Study of Transfusion-Transmitted Infections
For Condition: Virus Disease
Status: Recruiting
Sponsor(s): Warren G Magnuson Clinical Center (CC) ,
Synopsis: This study will follow blood transfusion recipients for 6 to 9 months following transfusion to monitor the quality and safety of blood transfusion. Improved viral testing and careful donor screening in the last several years has dramatically reduced the rates of transfusion-related HIV and hepatitis. Nevertheless, ongoing surveillance of transfusion-related infections is essential to maintain a high safety standard and to determine the transfusion risk of other infectious agents, such as cytomegalovirus, Epstein-Barr virus, parvovirus B-19, HHV-8 (Kaposi's sarcoma virus) and other possible hepatitis viruses that might be blood-transmitted. Transfused patients' blood will be tested for various infectious agents. Their blood samples and blood samples from their donors will be frozen and stored in a repository so that any new infectious agent can be rapidly evaluated for its danger to the safety of the blood supply. Adult patients at the National Institutes of Health and children at the Children's National Medical Center who are scheduled to receive a blood transfusion or to undergo surgery for which a blood transfusion may be needed are eligible for this study. All participants will have a 20- to 25-milliliter (about 2 tablespoonfuls) blood sample drawn before their transfusion and again at 1, 2, 3 and 6 months after the transfusion. Patients who are transfused on more than one occasion over the course of the study will provide three additional monthly samples. Patients who develop a transfusion-transmitted infection during the study will provide up to four more samples to study the infection and its effects. Participants will complete a brief questionnaire at the end of the study regarding prior blood transfusions and the development of any illnesses, such as hepatitis, that might have been caused by the transfusion.
Details: Improved viral screening assays and more intensive questioning of donors for high-risk behaviors have resulted in dramatic declines in the rates of transfusion-transmitted hepatitis and AIDS. Nonetheless, there is need for continued vigilance of the safety of blood supply. This study will enroll blood donors and prospectively followed blood recipients in order to: 1) establish ongoing surveillance of the incidence of breakthrough infections from transfusion-transmitted agents for which there are existing donor-screening assays (e.g. HBV, HCV, HIV, human T cell lymphotropic virus [HTLV]); 2) monitor the transfusion risk of established infectious agents that are not routinely screened in blood donors including CMV, EBV, parvovirus B-19, HHV-8 [Kaposi's sarcoma virus], and the recently described SEN and TT viruses (possible hepatitis agents); 3) establish a respository of linked donor and recipient samples so that any newly emerging infectious agent can be rapidly evaluated for its threat to the blood supply. The risk of these blood transmitted infections will be assessed by molecular and serologic assays in adult patients at NIH and in children at Children's National Medical Center. Blood samples from recipients transfused on one occasion will be obtained pre and 4,8,12, and 24 weeks post-transfusion. Recurrently transfused patients will have additional samples at 16 and 20 weeks after the index transfusion and 24 weeks after the last eligible transfusion. After initial infectious disease testing, recipient samples and linked donor samples will be stored in a repository maintained by the National Heart, Lung, and Blood Institute. The availability of the repository will allow for the assessment of transfusion risk for newly emerging pathogens and also for known agents for which there is no practical assay currently available. For example, this would allow future testing for prions in new variant Creutzfeld-Jacob disease (human variant of mad cow disease) or testing for the trypanosome that causes Chagas disease. Informed consent will be obtained to store and later test samples in the repository. Testing will be limited to infectious agents that potentially threaten the blood supply. No genetic testing will be performed.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA All adult ( greater than 18 years) patients who are transfused at NIH will be eligible if: 1) they have not been transfused in the 6 weeks preceding the index transfusion; 2) a pre-transfusion sample is available from the recipient; 3) they have a life-expectancy that exceeds 6 months; 4) they are expected to remain in the continental USA for at least six months post the index transfusion; 5) they provide informed consent.
Total Enrollment: 2800
Location and Contact Information:
Warren G. Magnuson Clinical Center (CC) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 010231; 01-CC-0231
Study Start Date: August 15, 2001
Record last reviewed: July 17, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00023023
Other Virus Disease Studies:
1. Study of Transfusion-Transmitted Infections
2. Collection of Liver Tissue for Virologic Studies
Related Studies:
Other Virus Disease Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Study of Transfusion-Transmitted Infections
|
|
|
|
|
|
|
|
